The Fight Against Cervical Cancer  by unknown
EBioMedicine 2 (2015) 1
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comEditorialThe Fight Against Cervical CancerGlobally, cervical cancer is one of the most deadly forms of cancer
affectingwomen—killingmore than 270,000 people every year. Thema-
jority of these deaths (85%, according to theWHO) occur in developing
countries. A global health priority, therefore, is to provide low-cost,
highly effective cervical cancer prevention, detection, and control
options to all women who need them.
The human papillomavirus (HPV) family is a group of about 150
related viruses, a subset of which is thought to be responsible for the
majority of cervical cancer cases. One of themost successful translation-
al achievements in cervical cancer research in recent years is the
development of highly effective preventative vaccines which directly
target these oncogenic HPV strains. The bivalent vaccine Cervarix(r)
(speciﬁc for HPV-16 and -18 strains) and the quadrivalent vaccine
Gardasil(r) (which is additionally speciﬁc for HPV-6 and -11) contain
viral L1 proteins from these strains, which are able to self-assemble
into virus-like particles (VLPs). Recently, Gardasil(r) 9 has been ap-
proved by the United States FDA which will contain an additional 5
strains of HPV not currently covered by available vaccines. These vac-
cines induce antibody responses against HPV, but do not contain any
of the viral genomic DNA present in natural viruses and, therefore, are
not able to establish an infection. Available data indicate that these vac-
cines are highly effective at preventing precancerous cell induction in
women, and since their introduction, global HPV infection rates appear
to be declining.
Although these prophylactic vaccines are highly effective at
preventing new infections, neither vaccine is capable of inducing im-
mune responses against established HPV infections. A major healthcare
goal, currently, is to develop therapeutic approaches to resolving poten-
tially cancerous HPV lesions (otherwise known as cervical intraepithelial
neoplasia (CIN), or cervical dysplasia). Several approaches are underway,
including a therapeutic vaccine which is likely to work by inducing an
adaptive T cell-mediated response against the viral E6 and E7 proteins,
which are expressed in these lesions. Several drugs are also being ex-
plored, including an antibody (bevacizumab) against vascular endothelial
growth factor (VEGF), whichmay help patients by limiting the growth of
new blood vessels to the cancer. Clinical trials are underway to test
whether chemotherapy drugs or immune checkpoint inhibitors such as
ipilimumab may work well in combination with radiation therapy.
Autologous T cell transfers, where the patients own immune cells arehttp://dx.doi.org/10.1016/j.ebiom.2015.01.001
2352-3964/© 2015 Published by Elsevier B.V.“trained” outside of the body to attack cancerous cells infected with
HPV are also being explored. Armedwith a basic scientiﬁc understanding
of howHPV replicates andmay contribute to cervical cancer, and how the
patient's own immune system may be “kicked into gear” in order to at-
tack those cancer cells has given researchers several potential avenues
which may already be explored as treatment options.
In addition to established principles about viral replication and
immune system function, scientists are also using systems approaches
to identify new genetic markers which are common in transformed
cervical lesions, and ongoing studies are looking at the basic molecular
mechanisms of how HPV-infected cervical cells become cancerous.
These basic approaches may help researchers identify and manipulate
new molecular pathways that are biologically relevant for cervical
cancer transformation, and which may be amenable to therapeutic
manipulation.
Although several promising treatment and prevention options are
available or under development, early detection remains one of our
most effective tools for combating cervical cancer. The Pap test, intro-
duced in the 1950s, is a simple means of screening cervical cells for
abnormalities and may now be combined with HPV DNA screening to
identify those patients at greatest risk for developing cervical cancer. Al-
though highly effective, the Pap test may not be a practical screening
tool for low-resource countries, and there is an urgent need for develop-
ment and effective implementation of inexpensive, easily-administered
screening options for these women—such as HPV DNA screening
kits that may not necessarily need expensive refrigeration or a well-
equipped laboratory to administer. Visual inspection with acetic acid
(VIA) is an inexpensive option currently in practice, but this method
may not be as accurate as DNA testing.
We have come a long way since the introduction of the Pap test.
Identiﬁcation of HPV as the major etiological agent of cervical cancer,
for example, has allowed rational vaccine design and the development
of targeted immunotherapies. However, there is still much work to do
to improve practical screening options in developing countries, and to
add to our arsenal of treatment options for established HPV infections.
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